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Background: This study compared individuals whose clinical diagnosis of Alzheimer’s disease (AD) matched or did
not match neuropathologic results at autopsy on clinical and functional outcomes (cognitive impairment, functional
status and neuropsychiatric symptoms). The study also assessed the extent of potentially inappropriate medication
use (using potentially unnecessary medications or potentially inappropriate prescribing) among misdiagnosed
patients.
Methods: Longitudinal data from the National Alzheimer’s Coordinating Center Uniform Data Set (NACC-UDS,
2005–2010) and corresponding NACC neuropathological data were utilized to compare 88 misdiagnosed and 438
accurately diagnosed patients.
Results: Following adjustment of sociodemographic characteristics, the misdiagnosed were found to have less
severe cognitive and functional impairment. However, after statistical adjustment for sociodemographics, dementia
severity level, time since onset of cognitive decline and probable AD diagnosis at baseline, the groups significantly
differed on only one outcome: the misdiagnosed were less likely to be depressed/dysphoric. Among the
misdiagnosed, 18.18% were treated with potentially inappropriate medication. An additional analysis noted this rate
could be as high as 67.10%.
Conclusions: Findings highlight the importance of making an accurate AD diagnosis to help reduce unnecessary
treatment and increase appropriate therapy. Additional research is needed to demonstrate the link between
potentially inappropriate treatment and adverse health outcomes in misdiagnosed AD patients.
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Alzheimer’s disease (AD) is a progressive neurodegenerative
disease and is the most common cause of dementia, ac-
counting for about 60% of all cases [1]. The clinical diagno-
sis of AD is a challenging evaluation process that follows
established clinical criteria and requires elimination of other
potential causes for dementia [2,3]. Various studies have
previously assessed the accuracy of the clinical diagnosis of
AD based on autopsy results, or the “gold standard.” A re-
cent and comprehensive study showed that depending on* Correspondence: gaug0015@umn.edu
1Center on Aging, School of Nursing, University of Minnesota, Minneapolis,
MN, USA
Full list of author information is available at the end of the article
© 2013 Gaugler et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the orthe permissiveness of clinical and neuropathologic criteria,
sensitivity ranged from 70.9% to 87.3% and specificity
ranged from 44.3% to 70.8% [4]. This and other studies
found that between 12% and 23% of patients diagnosed
with AD do not have sufficient AD pathology at autopsy to
account for the presence of dementia (“misdiagnosed”)
[5-9].
The observed misdiagnosis rate may be partly driven by
the fact that numerous conditions can mimic symptoms of
AD [2]. Some of these conditions constitute other types of
progressive dementias (e.g., frontotemporal dementia, vas-
cular dementia and dementia with Lewy bodies) while
others may be treatable and possibly reversible conditions
(e.g., drug intoxication, depression, nutritional deficiencies,l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lysis of clinical trials, 63% of deceased patients who were
clinically diagnosed with AD while alive were found to have
AD with other pathology [12]. In addition, older persons
appear to have more etiologies than younger individuals
which potentially attenuates the accuracy of clinical AD
diagnosis [13]. Other studies have found higher levels of
concordance between clinical and post-mortem diagnosis
of AD but diminished diagnostic accuracy with other types
of dementia [14,15].
Ruling out AD may result in changing patients’ man-
agement plans that can lead to further evaluation and
testing for the true underlying cause. Excluding AD may
also enable appropriate treatment of the true underlying
condition. A number of medications have been identified
as potentially unnecessary for patients with frontotem-
poral dementia [16-20] and dementia with Lewy bodies
[21,22], whereas treatment with statins, antiplatelet
agents and anticoagulants is deemed appropriate for pa-
tients with cerebrovascular disease.
At present limited information is available on the clinical,
functional and socio-demographic characteristics of per-
sons who have been misdiagnosed with AD based on neu-
ropathologic results [23]. Similarly, it is unknown whether
misdiagnosis of AD is associated with potentially unneces-
sary treatment or may result in patients not receiving treat-
ments that are more appropriate for their conditions. To
help address this knowledge gap we expanded on the study
by Beach et al. [4] which identified individuals whose clin-
ical diagnosis matched or mismatched their diagnosis per
neuropathologic examination post-mortem. Using data col-
lected as part of the National Alzheimer’s Coordinating
Center Uniform Data Set (UDS) (NACC-UDS) between
2005 and 2010, Beach and colleagues identified 88 partici-
pants misdiagnosed with AD and 438 participants accur-
ately diagnosed with AD [5]. The goal of our study was to
address two specific research questions: 1) When compared
to accurately diagnosed AD patients, do misdiagnosed
patients vary significantly on sociodemographic characteris-
tics, health history, and key clinical and functional out-
comes (cognitive impairment, functional status and
neuropsychiatric symptoms); and 2) What is the extent of




The National Alzheimer’s Coordinating Center (NACC)
[24] serves as the primary repository and data hub of the
34 past and present National Institute on Aging Alzhei-
mer’s Disease Centers (ADCs). Alzheimer’s Disease Cen-
ters are located throughout the United States, are based
in university medical centers, and are largely in urban
areas [4]. Recruitment occurs through referrals fromneurologists as well as community outreach efforts. The
NACC Uniform Data Set (or NACC-UDS) is a publicly
accessible, longitudinal database that includes standard-
ized cognitive, behavioral, and functional data for each
ADC participant based on their annual visits. The
NACC-UDS was initiated in 2005. Of particular rele-
vance to the current study, the NACC-UDS includes
longitudinal data on persons with different etiologies of
dementia as well as individuals not diagnosed with de-
mentia. The procedure of AD clinical diagnosis (in living
subjects) ranges from that of a consensus panel to a
single physician according to each ADC’s diagnostic
protocol; however, each ADC generally adheres to stan-
dardized clinical criteria as outlined by the DSM-IV or
NINDS-ADRDA guidelines [25]. The NACC-UDS pro-
vides systematic information on the following domains:
demographics, behavioral status, cognitive testing, med-
ical history, family history, clinical impressions, and
diagnoses. For more detail on the construction of the
NACC-UDS, please see Morris et al. [26]. Ethical
approval for the current study was provided by the
University of Minnesota Institutional Review Board
(IRB#1108E03546).
Participants in the current analysis were previously
identified in Beach et al.’s study [4]. NACC-UDS data
from 2005–2010 were considered for participants that
had at least one UDS assessment, had died, and had
brain autopsy results available (n = 1198). Of these indi-
viduals, 279 were excluded because they were considered
“not demented” during regular UDS assessments or did
not have data entered in key diagnostic entry fields (i.e.,
presence or absence of clinically probable AD and
CERAD plaque density or Braak stage) [4].
Of these remaining 919 individuals, two subgroups were
the focus of the current analysis. Those in the accurately di-
agnosed group received a primary clinical diagnosis of
probable AD based on NINDS-ADRDA criteria [26] and
also received a neuropathological diagnosis/verification of
AD per moderate or frequent density on the CERAD neur-
itic plaque density score [25] and a Braak neurofibrillary
tangle stage of III-VI [27]. The classification of those accur-
ately diagnosed with probable AD was based on a compre-
hensive analysis using various thresholds of CERAD
neuritic plaque density score and Braak neurofibrillary tan-
gle stages to find those with the greatest predictive value by
Beach and colleagues (n = 438; see p. 268). Those in the
misdiagnosed group received a primary clinical diagnosis of
probable AD but did not meet the aforementioned neuro-
pathological threshold for AD at autopsy (i.e., a moderate
or frequent CERAD density score or a Braak neurofibrillary
tangle stage of III-VI; n = 88). The primary neuropathologic
diagnoses of those in the misdiagnosed group included pri-
mary neuropathologic diagnosis of AD despite a low level
of AD histopathology (n = 17), tangle-only dementia or
Gaugler et al. BMC Geriatrics 2013, 13:137 Page 3 of 10
http://www.biomedcentral.com/1471-2318/13/137agryophilic grain disease (n = 15), frontotemporal lobar de-
generation (n = 15), cerebrovascular disease (n = 10), Lewy
body disease, with or without AD (n = 9), hippocampal
sclerosis, with or without AD (n = 9), progressive supra-
nuclear palsy (n = 3), corticobasal degeneration (n = 2), neu-
roaxonal dystrophy/Hallevorden-Spatz-like condition
(n = 2), and miscellaneous (n = 6; 1 case each of amyloid
angiopathy, “small vessel disease,” “TDP-43 proteinopathy,”
limbic encephalitis, Rosenthal fiber encephalopathy, “clin-
ical dementia, no neuropathological substrate”) [4].
In the original Beach et al. analysis, subjects were diag-
nosed with possible AD (n = 126) using NINDS-ADRDA
guidelines [26]. These individuals had a neuritic plaque
density average of 2 (SD = 1.2; 0 = none; 1 = sparse;
2 =moderate; and 3 = frequent) and a Braak stage mean
of 4.2 (SD = 1.6) at death. Another subgroup of partici-
pants (n = 271) was classified as not having either prob-
able or possible AD based on NINDS-ADRDA
guidelines, and of these a substantial proportion had a
neuropathological diagnosis of AD (n = 107; “false nega-
tives”) or other neuropathological diagnoses: frontotem-
poral lobar degeneration (n = 60), Lewy body disease
with or without AD (n = 31), Creutzfeldt-Jakob disease
and other prior encephalopathies (n = 23), progressive
supranuclear palsy (n = 18), tangle-only dementia or ar-
gyrophilic grain disease (n = 9), corticobasal degener-
ation (n = 8), Pick’s disease (n = 6), cerebrovascular
disease (n = 6), hippocampal sclerosis with or without
AD (n = 2), amyotrophic lateral sclerosis (n = 2), and
miscellaneous (1 case each of neuronal intermediate fila-
ment disease, “leukodystrophy,” and cerebellar atrophy;
n = 3). As one of the aims of the current study was to
examine whether potentially inappropriate medication
use occurred among those who were misdiagnosed as
having probable AD [4], those in the possible AD group
as well as the false and true negatives in the original
Beach et al. analysis were excluded.
Measures
The following measures available at the first time a
probable AD diagnosis was recorded in the NACC-UDS
were included. Socio-demographic/background charac-
teristics included age, gender, race (Caucasian vs. non-
Caucasian), education (years), marital status (married/
living as married or not), and living alone (yes/no).
Health history and conditions included any family his-
tory of dementia (a parent with dementia, a sibling with
dementia and number of other relatives with dementia),
health history (any history of cardiovascular disease,
cerebrovascular disease, parkinsonian features, other
neurologic conditions, medical/metabolic conditions),
etiology of AD (AD only or a mixed etiology), and living
in a nursing home (yes/no). Since individuals who par-
ticipated in the NACC-UDS may have received anAlzheimer’s disease diagnosis prior to enrollment (and
time of diagnosis prior to NACC-UDS was not re-
corded), two additional variables were included to ad-
dress potential heterogeneity of disease stage. A
dichotomous variable identified those who were re-
corded as having or not having a probable AD diagnosis
at baseline in the NACC-UDS. Informants also reported
on participants’ years since onset of cognitive decline at
the initial NACC-UDS visit. Severity of cognitive impair-
ment was measured with the Mini-Mental Status Exam-
ination/MMSE (mean score and level of cognitive
impairment: normal >24, mild 21–24, moderate 10–20
and severe < =9) [28]. Functional status was assessed
with the Functional Assessment Questionnaire/FAQ
(total score and proportion of patients with impaired
functioning, per total score of 9 or above) [29]. Neuro-
psychiatric symptomatology was measured with the
Neuropsychiatric Inventory Questionnaire/NPI-Q (total
score) [30]. Due to extensive missing data on the Geriat-
ric Depression Scale/GDS [31] in the accurately diag-
nosed group (approximately 30%), depression was
assessed using other available measures: a) proportion of
depressed subjects who had a “yes” response per the
NPI-Q depression or dysphoria item completed by infor-
mants of the NACC-UDS participant; and b) severity of
depression among subjects identified as depressed/dys-
phoric on the NPI-Q, also completed by informants.
Use of potentially inappropriate medications
Data on medication use at or following the first assessment
which subjects’ probable AD diagnosis was recorded in the
NACC-UDS were considered. The identification of poten-
tially inappropriate medications (the use of potentially
unnecessary medications or potentially inappropriate pre-
scribing) was deemed feasible for 3 specific subgroups
within the misdiagnosed group based on prior research:
those diagnosed post-mortem with either frontotemporal
dementia (FTD, n = 18), dementia with Lewy bodies (DLB,
n = 9), or cerebrovascular disease (n = 10) [4,18,20,21,32].
Prior to start of the analysis, a neurologist at Eli Lilly and
Company created an appropriate and potentially inappro-
priate medication matrix list based on the NACC-UDS
medication checklist. Classification of potentially inappro-
priate medications was then based on clinical treatment
guidelines and available research evidence.
The use of acetylcholinesterase inhibitors was considered
potentially inappropriate for subjects whose true diagnosis
was FTD at autopsy [20]. A previous study evaluating done-
pezil in the treatment of FTD relative to matched, un-
treated FTD patients over six months found that a third of
the treated patients experienced increased disinhibited or
compulsive acts, which abated with discontinuation of
the medication [33]. These and similar observations
have prompted a general recommendation to avoid
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randomized controlled trials also suggest that memantine
lacks efficacy in the treatment of FTD [34].
The use of antipsychotics, except for quetiapine or clo-
zapine, is considered potentially inappropriate for pa-
tients with dementia with Lewy bodies (DLB) as these
individuals may experience severe side effects or fatal
complications if behavioral symptoms are treated with
antipsychotic drugs [35]. Patients with DLB are particu-
larly sensitive to developing extrapyramidal symptoms
and potentially fatal complications of neuroleptic sensi-
tivity, which affects approximately 50% of DLB patients.
Administering antipsychotic medications for behavioral
symptoms to patients with DLB can potentially result in
serious neuroleptic sensitivity reactions which are associ-
ated with significantly increased morbidity and mortality
[21,22].
To further assess whether participants in the misdiag-
nosed group were subject to potentially inappropriate
prescribing, we determined the number of participants
in the misdiagnosed group with cerebrovascular disease
who did not use statins, antiplatelet agents or anticoagu-
lants. These medications are considered appropriate for
those with cerebrovascular disease [33]. Thus, the use of
potentially inappropriate medication was defined as (a)
the use of an anti-dementia drug by those whose true
diagnosis was found at autopsy to be FTD, or (b) the use
of an antipsychotic drug by those whose true diagnosis
was found at autopsy to be DLB, or (c) not being treated
with statins, antiplatelet agents or anticoagulants by
those whose true diagnosis was found at autopsy to be
cerebrovascular disease.
As a sensitivity analysis, the use of potentially inappro-
priate medications was also assessed using a broader def-
inition which included the above criteria or the use of
an anti-dementia drug by any of the misdiagnosed pa-
tients (i.e., not confined to those found to have FTD at
autopsy). The rationale for broadening the definition
was that anti-dementia drugs have an approved indica-
tion for the treatment of AD, whereas there is a lack of
evidence-based support for non-AD/misdiagnosed indi-
viduals receiving such pharmacological intervention
[36]. The “off label” use of anti-dementia drugs was,
therefore, considered potentially unnecessary for the
misdiagnosed subjects in the study. Notably, there is an
anti-dementia drug (rivastigmine) that is indicated for
dementia due to Parkinson’s disease but none of the
misdiagnosed in the current study were diagnosed with
this condition.
Analysis
The principal objective of this analysis was to statistically
compare the misdiagnosed and accurately diagnosed
groups on sociodemographics, health history, and clinicaland functional outcomes (cognitive impairment, functional
status, and neuropsychiatric symptoms) as assessed at the
first UDS assessment for which a clinically probable AD
diagnosis was recorded in the NACC-UDS. Group compar-
isons for all variables were first conducted using unadjusted
bivariate analysis (e.g., unadjusted logistic or multinomial
regressions for categorical variables, T-tests for continuous
measures). To assess whether the groups significantly dif-
fered on key outcomes (severity of cognitive impairment,
functional status, and neuropsychiatric symptoms) when
their core demographic characteristics, time since onset of
cognitive decline and dementia severity were held constant,
we conducted two sets of adjusted analyses: one controlling
for participants’ key sociodemographic characteristics (age,
education, gender, race, and marital status) and the second
controlling for the aforementioned sociodemographics as
well as time since onset of cognitive decline, a probable AD
diagnosis at baseline of the NACC-UDS (yes/no), and de-
mentia severity (categorical, as assessed by MMSE levels
noted above). The second adjusted analysis was performed
because dementia severity, the presence of probable AD
diagnosis at baseline, and time since symptom onset are
core clinical characteristics of AD and are correlated with
other key clinical and functional outcomes. Analyses of co-
variance were used for continuous outcomes and logistic or
multinomial logistic regression analyses were used for cat-
egorical outcomes.
An additional study objective was to examine poten-
tially inappropriate medication use by the misdiagnosed
group. Using data on medication use at or following the
first assessment when subjects’ probable AD diagnosis
was recorded in NACC-UDS, we identified potentially
inappropriate medication use for all misdiagnosed par-
ticipants. SAS version 9.3 [37] was used to extract data
and perform all analyses.
Results
Sociodemographic background characteristics and health
history
Participant socio-demographic characteristics, health
history, and bivariate comparisons between the misdiag-
nosed and accurately diagnosed groups are presented in
Table 1. Participants in the misdiagnosed group were
significantly (p < .05) older than those in the accurately
diagnosed group (83.52 years vs. 78.72 years, respect-
ively), were more likely to live alone (17.05% vs. 4.11%,
respectively), and were less likely to be married (56.82%
vs. 71.00%, respectively) at the time of study entry or
first AD diagnosis. For all other socio-demographic char-
acteristics, the two diagnostic groups did not signifi-
cantly differ. A significantly higher proportion of
individuals in the misdiagnosed group had a history of a
cardiovascular condition (47.13%) than did those in the
accurately diagnosed group (31.49%). Those in the












Age, Mean ± SD 83.52 ± 10.31 78.72 ± 10.27 −4.80 <.0001
Years of education, Mean ± SD 14.53 ± 3.56 14.90 ± 3.34 0.37 .3528
Gender, N,% male 52, 59.09 254, 57.99 0.96 (0.60, 1.52) .8490
Race, N,% minority 5, 5.68 24, 5.48 0.96 (0.36, 2.59) .9388
Race .
White, N/% 83, 94.32 414, 94.52 (Ref)
Black, N/% 3, 3.41 17, 3.88 1.14 (0.33, 3.97) .8414
Asian, N/% 1, 1.14 4, 0.91 0.80 (0.09, 7.27) .8444
Other, N/% 1, 1.14 3, 0.68 0.60 (0.06, 5.85) .6614
Unknown, N,%
Marital status, married/living as married, N,% 50, 56.82 311, 71.00 1.86 (1.16, 2.98) .0095
Living alone, N,% 15, 17.05 18, 4.11 0.21 (0.10, 0.43) <.0001
Health history and conditions
Family history of dementia
Number of “Other demented relatives,” Mean ± SD 0.41 ± 0.80 0.63 ± 1.20 0.22 .1971
Father or mother with dementia, N,% 23, 32.86 183, 47.78 1.87 (1.09, 3.20) .0225
Any sibling with dementia, N,% 4, 4.55 8, 1.83 0.39 (0.12, 1.33) .1339
Health history
Cardiovascular condition, N,% 41, 47.13 137, 31.49 0.52 (0.32, 0.82) .0055
Cerebrovascular condition N,% 18, 20.69 66, 15.28 0.69 (0.39, 1.24) .2127
Parkinsonian features, N,% 9, 10.23 39, 8.97 0.86 (0.40, 1.86) .7087
Other neurologic conditions, N,% 17, 20.00 87, 20.67 1.04 (0.58, 1.86) .8908
Medical/metabolic conditions, N,% 80, 90.91 361, 82.61 0.48 (0.22, 1.02) .0574
AD only vs. mixed etiology 56, 63.64 298, 68.04 0.82 (0.51, 1.33) .4225
Living in nursing home, N,% 13, 14.77 85, 19.41 1.39 (0.74, 2.62) .3103
Time since onset of cognitive decline (years) 6.30 ± 3.76 7.81 ± 4.01 1.51 .0016
Probable AD diagnosis at baseline 65, 73.86 412, 94.06 5.61 (3.02, 10.41) <.0001
Severity of cognitive impairment
MMSE, Mean ± SD 19.46 ± 7.66 12.93 ± 9.03 −6.53 <.0001
Normal (>24): N,% 22, 25.00 33, 7.53 1.00 (Ref)
Mild (21–24): N,% 23, 26.14 67, 15.30 1.94 (0.95, 3.98) .0699
Moderate (10–20): N,% 24, 27.27 136, 31.05 3.78 (1.89,7.55) .0002
Severe (<= 9): N,% 11, 12.5 137, 31.28 8.30 (3.67, 18.81) <.0001
Missing: N,% 8, 9.1 65, 14.84 5.42 (2.18, 13.48) .0003
Functional status
Functional activities questionnaire (FAQ), total score, Mean± SD, 20.96 ± 8.52 24.52 ± 7.10 3.55 <.0001
Impaired level of functioning, FAQ > =9, N,% 75, 88.24 405, 95.74 3.0 (1.33, 6.75) .0080
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Table 1 Socio-demographic and clinical characteristics of the misdiagnosed and accurately diagnosed groups:
unadjusted comparisons (Continued)
Neuropsychiatric symptoms
Neuropsychiatric inventory questionnaire (NPI-Q), total
score, Mean ± SD
4.84 ± 4.46 6.18 ± 5.35 1.35 .0364
Patients with depression and dysphoria (NPI-Q), N,% 16, 20.25 145, 37.08 2.32 (1.29, 4.17) .0048
Severity level for patients with depression and dysphoria
(NPI-Q), Mean ± SD
1.56 ± 0.73 1.40 ± 0.62 −0.16 .3276
NOTE: CI = Confidence interval, SD = standard deviation, AD = Alzheimer’s disease; MMSE =Mini Mental Status Examination.
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cantly longer time since onset of cognitive decline than
those in the misdiagnosed group (7.81 vs. 6.30 years, re-
spectively) and were more likely to have a probable AD
diagnosis at baseline (94.06% vs. 73.86%, respectively).
For all other health history and condition variables the
two groups did not significantly differ.
Severity of cognitive impairment and outcomes
Table 1 also provides detail on severity of cognitive im-
pairment, functional status, and neuropsychiatric symp-
toms (including depression). Individuals in the
misdiagnosed group scored significantly (p < .05) higher/
better on the MMSE (19.46) than those in the accurately
diagnosed group (12.93), with a lower percentage of mis-
diagnosed participants scoring within the “severe” cat-
egory (12.5% vs. 31.28%, respectively). The misdiagnosed
group also appeared less functionally impaired on the
FAQ, on average, and a smaller proportion scored above
the impaired clinical threshold than those in the accur-
ately diagnosed group (88.24% vs. 95.74%, respectively).
The misdiagnosed also had lower/better average neuro-
psychiatric scores on the NPI-Q than those in the accur-
ately diagnosed group (4.84 vs. 6.18, respectively). A
higher percentage of those in the accurately diagnosed
group had depression/dysphoria as measured on the
NPI-Q item than those in the misdiagnosed group
(37.08% vs. 20.25%, respectively), but the two groups did
not differ on the NPI-Q severity of depression indicator.
Adjusted analyses
We conducted a series of analyses to determine whether
the observed group differences in clinical and functional
variables were maintained following: a) adjustments for key
socio-demographics (age, gender, race, marital status and
education); and b) adjustments for key socio-demographics,
dementia severity level (MMSE categorical scores), time
since onset of cognitive decline, and whether probable AD
diagnosis was recorded at baseline (see Table 2). Following
adjustments for sociodemographic characteristics only, the
results paralleled those of the unadjusted bivariate com-
parisons; individuals in the misdiagnosed group hadsignificantly (p < .05) higher/better MMSE scores, had sig-
nificantly lower/better FAQ scores, and were less likely to
have depression/dysphoria on the NPI-Q. The NPI-Q total
score no longer varied significantly following the adjust-
ment of sociodemographic characteristics.
When including MMSE, time since onset of cognitive
decline and probable AD diagnosis at baseline along
with sociodemographics as covariates (see Table 2) the
two groups were found to statistically differ on only one
outcome: depression. A lower proportion of participants
in the misdiagnosed group was found to have depres-
sion/dysphoria on the NPI-Q (p = .0183).
We repeated the adjusted models with one sociodemo-
graphic variable as an outcome: living alone, as it is apt to
have clinical ramifications in our cognitively impaired sam-
ple. The misdiagnosed group was more likely to live alone
than those in the accurately diagnosed group (OR = .26,
95% CI = .11, .60, p = .0018) after adjusting for sociodemo-
graphic variables only. However, there was no significant
difference in living alone between the misdiagnosed and ac-
curately diagnosed groups after adjusting for sociodemo-
graphic variables, MMSE, time since onset of cognitive
decline and probable AD diagnosis at baseline (OR = .47,
95% CI = .18, 1.24, p = .1269).
Medication use in the misdiagnosed group
Results on medication use among the 88 misdiagnosed
subjects were based on 145 observations at or after a
probable AD diagnosis was recorded in the NACC-UDS.
Among the misdiagnosed subjects, 18.18% (16 of 88)
were on a potentially inappropriate medication regimen.
When using the broader definition of potentially in-
appropriate medication, this rate increased to 67.1% (59
of 88). Among the misdiagnosed subjects in the FTD,
DLB, or cerebrovascular subgroups, 43.2% (16 of 37)
were classified as being on a potentially inappropriate
medication regimen. This is based on pooling the follow-
ing results: a) 55.5% of misdiagnosed subjects who were
identified at autopsy as having FTD (10 of 18) were
treated with acetylcholinesterase inhibitors or glutamate
blockers; b) 11.1% of misdiagnosed subjects who were
identified at autopsy as having DLB (1 of 9) were treated










Severity of cognitive impairment
MMSE (Mean) −5.90 <.0001
Normal (>24) 1.00 (Ref)
Mild (21–24) 2.20 (1.04, 4.65) .0388
Moderate (10–20) 4.27 (2.07, 8.80) <.0001
Severe (<= 9) 8.16 (3.48, 19.15) <.0001
Missing 5.93 (2.30, 15.30) .0002
Functional status
Functional activities questionnaire
(FAQ), total score (Mean)
3.24 .0003 −0.90 .1823
Impaired level of functioning, FAQ > =9 2.56 (1.11, 5.93) .0281 1.09 (0.40, 2.92) .8703
Neuropsychiatric symptoms
Neuropsychiatric inventory questionnaire
(NPI-Q), total score (Mean)
0.81 .2018 0.55 .4222
Patients with depression and dysphoria
(NPI-Q)
1.99 (1.09, 3.63) .0251 2.15 (1.14, 4.07) .0183
Severity level for patients with depression
and dysphoria (NPI-Q)
−0.18 .2697 −0.21 .2327
NOTE: CI = Confidence interval, SD = standard deviation, MMSE =Mini Mental Status Examination; Analyses of covariance were used for continuous outcomes.
aAdjusted for age (continuous – in years), education (continuous – in years), gender, race (white vs. minority), and marital status (married vs. other).
bAdjusted for age (continuous – in years), education (continuous – in years), gender, race (white vs. minority), marital status (married vs. other), dementia severity
(MMSE), time since onset of cognitive decline, and probable AD diagnosis at Time 1.
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50% of misdiagnosed subjects who were identified at
autopsy as having a cerebrovascular disease (5 of 10)
were not treated with a statin, antiplatelet agent, or anti-
coagulant (the treatments considered appropriate for
such conditions). The overall percentage of those in the
misdiagnosed group who were treated with an anti-
dementia drug at the time a probable AD was recorded
in the NACC-UDS or thereafter was 64.8%.
Discussion
This study compares characteristics of persons with an
inaccurate AD diagnosis (i.e., a clinical diagnosis of AD
but no neuropathological verification of AD) and an ac-
curate AD diagnosis (those with a matching clinical and
neuropathological diagnosis of AD at autopsy). Similar
to other recent studies, the current analysis found that
the misdiagnosed and accurately diagnosed groups sig-
nificantly differed on several clinical and functional out-
comes even after controlling for sociodemographic
characteristics. When compared to the accurately diag-
nosed group, the misdiagnosed group was significantly
older, less likely to be married, more likely to live alone,
and more likely to have a history of cardiovascular con-
ditions [23]. The misdiagnosed group also had a less se-
vere illness profile in terms of dementia severity, familyhistory of dementia, functional status and neuropsychi-
atric symptoms (including the presence of depression or
dysphoria). This may have been due to the groups’ vari-
ation in their dementia trajectories; individuals in the ac-
curately diagnosed group had experienced cognitive
decline for approximately 1½ years longer, on average,
than those in the misdiagnosed group. Similarly, a higher
proportion of individuals in the accurately diagnosed
group had a probable AD diagnosis at baseline than
those in the misdiagnosed group. The groups did not,
however, significantly differ on neuropsychological
symptoms (including severity of depression) following
adjustment of core sociodemographic characteristics.
Interestingly, although the misdiagnosed patients were
older, they had a shorter duration of symptoms and thus
the onset of their decline was at 77 years of age vs.
71 years of age for accurately diagnosed patients. The
younger age of onset may predispose these patients to
less complicated pathology whereas the misdiagnosed,
because of their older age, may be more vulnerable to
other conditions (e.g., cardiovascular) [23] that can mas-
querade as AD. Similarly, one reason for misdiagnosis
occurring among patients with cardiovascular conditions
is due to multiple pathologies occurring at autopsy,
which is a common occurrence even in fairly restricted
clinical trial samples of AD patients [12].
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for age, gender, race, marital status, education, dementia
severity, time since onset of cognitive decline and
whether one had a probable AD diagnosis at baseline
the two groups no longer differed significantly on any
clinical or functional measure except for a single depres-
sion parameter. Those misdiagnosed were less likely to
have depression or dysphoria when compared to the ac-
curately diagnosed group. This depression-related find-
ing should be evaluated with caution, as it was based on
a single item and the groups did not significantly differ
on the severity of depression parameter. Considering the
non-specific nature of clinical diagnosis of dementia
symptoms [4], current evaluation processes of AD diag-
nosis may not enable clinicians to differentiate misdiag-
nosed and accurately diagnosed patients in routine
practice when patients have similar levels of cognitive
impairment, socio-demographics and time since symp-
tom onset. This scenario would, however, be different
once these patients are not of similar dementia severity
level or time since symptom onset as suggested in our
adjusted models of sociodemographic characteristics
only (as those in the misdiagnosed group tended to have
a more recent time since symptom onset as well as less
severe cognitive, functional and neuropsychiatric
impairment).
The findings also suggested that 18.2% of individuals in
the misdiagnosed group were on a potentially inappropriate
medication regimen. This percentage may be clinically
meaningful as such practice could adversely and inordin-
ately influence misdiagnosed patients’ health outcomes and
lead to increased burden to patients, their caregivers, their
physicians and healthcare payers. Moreover, when using a
broader definition of “potentially inappropriate medication”
the rate could be as high as 67.1%. The latter finding ap-
pears driven by the 64.8% of misdiagnosed patients who
were treated with anti-dementia drugs. The potential per-
sonal and economic ramifications of such extensive “off
label” use of anti-dementia drugs are unclear and will re-
quire future study. It is important to note that although
anti-dementia drugs are indicated for the treatment of AD,
treating those in the misdiagnosed group with an acetyl-
cholinesterase inhibitor or a glutamate blocker is likely not
inappropriate in all circumstances as such medications are
often the practical and pragmatic therapeutic strategy for
individual clinicians. Patients with non-AD dementias may
also have a positive response to acetylcholinesterase inhibi-
tors or glutamate blockers in some instances. Nonetheless,
an accurate clinical/in vivo diagnosis is necessary in order
to tailor treatment of actual underlying conditions rather
than broad non-specific clinical syndromes.
The current study helps to highlight the importance of
making an accurate diagnosis of AD in clinical practice. Im-
proving diagnostic accuracy in clinical settings, andespecially ruling out AD, may help reduce unnecessary
treatment as well as increase the administration of appro-
priate therapy for patients’ conditions. There are growing
efforts to improve diagnostic accuracy of AD, including the
use of biomarker testing and especially biomarkers with
evidence for compelling negative predictive value (i.e., when
a patient’s test is negative it is most likely correct) [2,38,39].
Given the clinical complexity of distinguishing between po-
tentially misdiagnosed and accurately diagnosed patients as
demonstrated by our empirical results, biomarkers may
provide a useful tool to clinicians to avoid or minimize pos-
sible misdiagnosis. Recent studies have found, for example,
that the knowledge of beta amyloid positron emission tom-
ography scan results can lead to substantial changes to cli-
nicians’ diagnoses and intended management plans [40,41].
Such findings suggest that the use of new, more accurate
diagnostic approaches may complement clinical diagnostic
procedures for select patients and help improve diagnostic
accuracy in clinical practice, especially decreasing the rate
of false positives. The goals of the current analysis were to
analyze key variations between those with accurately diag-
nosed AD and false positives, but in order to test the full
accuracy and value of such biomarkers samples must in-
clude not only “false positives” (e.g., the misdiagnosed
group in this analysis) but also false negatives to establish
both sensitivity and specificity. Moreover, it is likely there
are important ramifications for those who are not diag-
nosed with probable or possible AD but are later found to
have AD-related pathology (which is often mixed). This can
serve as an important focus for future descriptive and clin-
ical research on the health and cost outcomes of misdiag-
nosed AD.
The results need to be evaluated in light of several
study limitations. First, it is unclear whether the findings
can be generalized to patients evaluated in routine clin-
ical practice as subjects in this study were assessed at
National Institute on Aging Alzheimer’s Disease Centers
(ADCs) which are predominately urban, university med-
ical centers that have recruited mostly (approximately
90%) white participants [26]. Second, the current find-
ings on potentially inappropriate medication use were
based on a small sample size and will require replication.
Data on the medical rationale for the choice of treat-
ments were not available. Third, the high proportion of
participants in the NACC-UDS with a likely AD diagno-
sis before enrollment in the NACC-UDS, the annual fre-
quency of follow-up assessments in the NACC-UDS, the
relatively small number of available assessments after
the visit in which probable AD was first recorded, and
the fact that medication use was recorded in the 2 weeks
prior to a NACC-UDS assessment are among the other
study limitations. Infrequent assessments indicate fewer
opportunities to capture use of potentially unnecessary
medications, suggesting that the current findings may
Gaugler et al. BMC Geriatrics 2013, 13:137 Page 9 of 10
http://www.biomedcentral.com/1471-2318/13/137have underestimated the true prevalence of such
pharmacological therapies (as well as capturing use of
appropriate medications). Last is the extensive missing
data on the Geriatric Depression Scale which led to our
use of less robust depression parameters (neither of
which are empirically-validated measures of depression).
The statistical differences we found on the single item
measure of depression were reversed for those with
available GDS data (due in part to those with severe de-
mentia not completing the GDS in the NACC-UDS). Fi-
nally, the results should be considered in light of the fact
that some of the data are based on self-report without
the benefit of informant information to confirm diagno-
sis. As individuals who lived alone or were unmarried
were more likely to be misdiagnosed, clinicians may not
have had the same quality of data available for these
participants.
Conclusions
This study highlights the importance of making an accurate
diagnosis of AD in clinical practice (and especially ruling
out AD) in order to reduce potentially inappropriate treat-
ment for patients’ conditions. Additional research is re-
quired, however, to demonstrate the link between improved
diagnostic accuracy and impaired patients’ health out-
comes. A greater understanding of the empirical associa-
tions between inappropriate treatment and adverse health
outcomes in misdiagnosed AD patients would advance the
current state-of-the-art of clinical AD research.
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